Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
47.35
+0.04 (+0.08%)
Streaming Delayed Price
Updated: 1:06 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
45
46
Next >
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
June 08, 2022
Via
Benzinga
Bristol-Myers Squibb Whale Trades Spotted
June 06, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 25 strange trades.
Via
Benzinga
7 Cheap Growth Stocks That Won’t Stay That Way for Long
June 06, 2022
Investors foolishly sent these stocks into cheap territory, ignoring the near-term growth prospects that will reward them soon.
Via
InvestorPlace
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
June 05, 2022
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Via
Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
June 03, 2022
These biotech stocks face some key make-or-break events in June that could have big implication for their futures.
Via
InvestorPlace
What 7 Analyst Ratings Have To Say About Bristol-Myers Squibb
June 03, 2022
Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
June 03, 2022
Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY).
Via
InvestorPlace
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
June 03, 2022
Bristol Myers is moving deeper into the targeted oncology space.
Via
Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
Bristol-Myers Squibb Whale Trades Spotted
May 31, 2022
Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Sunshine Biopharma Prepares For IND Study Of Novel Cancer Drug That It Expects Could Beat Multidrug-Resistant Cancer
May 26, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Michael Burry Says 2022 Is a ‘Plane Crash.’ Here’s What the Legendary Investor Is Betting On.
May 24, 2022
Michael Burry is back on Twitter, although his first tweet upon his return is not very supportive of current market conditions.
Via
InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
May 24, 2022
The company is planning to soon ask for FDA approval of etrasimod in ulcerative colitis.
Via
Investor's Business Daily
Analyzing Bristol-Myers Squibb's Short Interest
May 23, 2022
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which...
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
Legendary Investor Michael Burry Is Betting Against Apple (AAPL) Stock
May 20, 2022
Dr. Michael Burry, who earned millions by betting against the housing market in 2008, has a new short position. This time it's on AAPL stock.
Via
InvestorPlace
9 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
May 17, 2022
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Looking At Bristol-Myers Squibb's Recent Whale Trades
May 17, 2022
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.
Via
Benzinga
7 ETFs to Pick-Up From the Tech Wreck
May 17, 2022
ETFs are a great way to use the current downturn in technology stocks to take advantage of long-term bargains.
Via
InvestorPlace
Michael Burry Is Betting Against Apple: Here's The Size Of 'The Big Short' Investor's Stake
May 16, 2022
Michael Burry has been known to take large positions against companies he thinks are overvalued.
Via
Benzinga
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
May 16, 2022
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come.
Via
Investor's Business Daily
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
May 12, 2022
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Top 10 Stocks Helping Warren Buffett Beat the Market
May 11, 2022
These Warren Buffett stocks are helping the Oracle of Omaha be a winner even in a down market. All are generating solid returns in 2022.
Via
InvestorPlace
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Bristol-Myers: "Boring Is Good"
May 09, 2022
The firm’s big money-making drug, Revlimid (acquired when it bought Celgene a few years back), which treats a cancer of plasma cells called multiple myeloma, is facing increasing generic competition.
Via
Talk Markets
9 Health Care Stocks With Whale Alerts In Today's Session
May 06, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.